Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Sponsor
Poitiers University Hospital
Study ID
NCT06200220
Status
Unknown

Conditions

  • Waldenstrom's Macroglobulinaemia Refractory

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.

Key Dates

Start date
Dec 28, 2023
Status verified
Dec 2023
Primary completion
Dec 28, 2023
Completion
Dec 1, 2025

Study Design

Enrollment
45 participants (estimated)

Primary Outcome Measure

Efficiency [ Time Frame: 2018 to 2025 ]

Central Contacts